European Study to Describe Hospital Stay in Patients Admitted for Acute Bipolar Manic Episodes

March 28, 2011 updated by: AstraZeneca

European Study to Describe Hospital Stay in Patients Admitted for Acute Bipolar Manic Episodes Treated With Immediate Release Quetiapine or Extended Release Quetiapine

This study is being carried out to find out how patients suffering from the acute manic phase of bipolar disease are currently managed with Quetiapine Immediate Release (IR) or Quetiapine Extended Release (XR) in the hospital setting in real life practice, including length of stay.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

1280

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Belgium
      • Assebroek, Belgium
        • Research Site
      • Bertrix, Belgium
        • Research Site
      • Brugge, Belgium
        • Research Site
      • Elsene, Belgium
        • Research Site
      • Gent, Belgium
        • Research Site
      • Godinne, Belgium
        • Research Site
      • Koksijde, Belgium
        • Research Site
      • Malle, Belgium
        • Research Site
      • Marchienne-au-Pont, Belgium
        • Research Site
      • Montignies-Sur-Sambre, Belgium
        • Research Site
      • Ottignies, Belgium
        • Research Site
      • Overpelt, Belgium
        • Research Site
      • Roeselaere, Belgium
        • Research Site
  • Croatia
      • Split, Croatia
        • Research Site
      • Zagreb, Croatia
        • Research Site
  • Denmark
      • Augustenborg, Denmark
        • Research Site
      • Bispebjerg, Denmark
        • Research Site
      • Br�nderslev, Denmark
        • Research Site
      • Odense, Denmark
        • Research Site
  • Finland
      • Helsingin Kaupunki, Finland
        • Research Site
      • Jyv�skyl�, Finland
        • Research Site
      • Kellokoski, Finland
        • Research Site
      • Tammisaari, Finland
        • Research Site
  • Germany
      • Berlin, Germany
        • Research Site
    • Baden-W�rttemberg
      • Ulm, Baden-W�rttemberg, Germany
        • Research Site
    • Bayern
      • Cham, Bayern, Germany
        • Research Site
      • Neu�tting, Bayern, Germany
        • Research Site
      • Regensburg, Bayern, Germany
        • Research Site
      • Wasserburg am Inn, Bayern, Germany
        • Research Site
      • W�rzburg, Bayern, Germany
        • Research Site
    • Mecklenburg- Vorpommern
      • Greifswald, Mecklenburg- Vorpommern, Germany
        • Research Site
    • Niedersachsen
      • Bielefeld, Niedersachsen, Germany
        • Research Site
      • Hildesheim, Niedersachsen, Germany
        • Research Site
      • Liebenburg, Niedersachsen, Germany
        • Research Site
    • Nordrhein-Westfalen
      • Bochum, Nordrhein-Westfalen, Germany
        • Research Site
  • Italy
      • Ascoli Piceno, Italy
        • Research Site
      • Bologna, Italy
        • Research Site
      • Cosenza, Italy
        • Research Site
      • Cuneo, Italy
        • Research Site
      • Ferrara, Italy
        • Research Site
      • Foggia, Italy
        • Research Site
      • Mestre, Italy
        • Research Site
      • Pisa, Italy
        • Research Site
      • Roma, Italy
        • Research Site
      • Sassari, Italy
        • Research Site
      • Teramo, Italy
        • Research Site
    • Brindisi
      • Ceglie Messapica, Brindisi, Italy
        • Research Site
      • San Pietro Vernotico, Brindisi, Italy
        • Research Site
    • Catanzaro
      • Lamezia Terme, Catanzaro, Italy
        • Research Site
    • Frosinone
      • Loc. S. Marciano (Sora), Frosinone, Italy
        • Research Site
    • Messina
      • S. Agata Militello, Messina, Italy
        • Research Site
    • Treviso
      • Conegliano, Treviso, Italy
        • Research Site
  • Turkey
      • Adana, Turkey
        • Research Site
      • Ankara, Turkey
        • Research Site
      • Ayd?n, Turkey
        • Research Site
      • Bolu, Turkey
        • Research Site
      • Diyarbakir, Turkey
        • Research Site
      • Elazig, Turkey
        • Research Site
      • Erzurum, Turkey
        • Research Site
      • Istanbul, Turkey
        • Research Site
      • Kayseri, Turkey
        • Research Site
      • Konya, Turkey
        • Research Site
      • Manisa, Turkey
        • Research Site
      • Samsun, Turkey
        • Research Site
      • Sanliurfa, Turkey
        • Research Site
      • Sivas, Turkey
        • Research Site
      • Trabzon, Turkey
        • Research Site
      • Zonguldak, Turkey
        • Research Site
  • United Kingdom
      • Bury St Edmunds, United Kingdom
        • Research Site
      • Coventry, United Kingdom
        • Research Site
      • Hull, United Kingdom
        • Research Site
      • Leeds, United Kingdom
        • Research Site
      • Leicester, United Kingdom
        • Research Site
      • London, United Kingdom
        • Research Site
      • Newcastle (Upon Tyne), United Kingdom
        • Research Site
    • Cheshire
      • Winsford, Cheshire, United Kingdom
        • Research Site
    • Kent
      • Dartford, Kent, United Kingdom
        • Research Site
    • London
      • Ealing, London, United Kingdom
        • Research Site
    • Merseyside
      • Prescot, Merseyside, United Kingdom
        • Research Site
    • Norfolk
      • Norwich, Norfolk, United Kingdom
        • Research Site
    • Somerset
      • Taunton, Somerset, United Kingdom
        • Research Site
    • Staffordshire
      • Cannock, Staffordshire, United Kingdom
        • Research Site
    • Surrey
      • Chertsey, Surrey, United Kingdom
        • Research Site
    • West Midlands
      • Wolverhampton, West Midlands, United Kingdom
        • Research Site
    • West Sussex
      • Pulborough, West Sussex, United Kingdom
        • Research Site
    • Yorkshire
      • Bradford, Yorkshire, United Kingdom
        • Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients diagnosed with Bipolar Disorder (ICD-10).admitted due to a acute manic episode and treated with quetiapine IR or quetiapine XR during the hospitalization period

Description

Inclusion Criteria:

  • Patients diagnosed with Bipolar Disorder (ICD-10).
  • Admitted for acute bipolar manic episode from 1st October 2009 to 1st October 2010
  • Patients treated with quetiapine IR or quetiapine XR during the hospitalization period.

Exclusion Criteria:

  • Patients in which BD is not the main reason for hospitalization
  • Patients admitted for acute bipolar mania episodes but finally diagnosed with mixed or bipolar disorder not otherwise specified (NOS) episodes
  • Patients receiving both quetiapine IR and XR during the same hospitalization period.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
1
patients admitted as for an acute bipolar manic episode and treated with quetiapine IR
2
patients admitted as for an acute bipolar manic episode and treated with quetiapine XR

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Length of hospital stay

Secondary Outcome Measures

Outcome Measure
Demographics
Use of resources
Treatments used

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

AstraZeneca

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2010

Primary Completion (Actual)

March 1, 2011

Study Completion (Actual)

March 1, 2011

Study Registration Dates

First Submitted

November 10, 2010

First Submitted That Met QC Criteria

November 10, 2010

First Posted (Estimate)

November 11, 2010

Study Record Updates

Last Update Posted (Estimate)

March 29, 2011

Last Update Submitted That Met QC Criteria

March 28, 2011

Last Verified

March 1, 2011

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • NIS-NEU-SER-2010/1

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Bipolar Manic Episode

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe